BIIB:NASDAQBiogen Inc. Analysis
Data as of 2026-08-25 - not real-time
$221.34
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
Biogen Inc. trades at $221.34, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. Over a rolling month the price has gained 15.3%. Momentum indicators put RSI at 62.5 (approaching overbought) with MACD reading bullish. The recent range runs from support at $199.58 up to resistance at $222.85.
Valuation screens as fair: a P/E of 39.3 sits above the sector average of 31.3. Sell-side targets cluster 6.4% above the current quote. Revenue is growing at 3.4% on a 8.3% profit margin.
Risk comes out at 3 of a possible 10, a low reading. With 30-day volatility of 33.7%, a beta of 0.27 and a maximum drawdown of 14.3%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to buy, carrying 5/10 conviction.
Valuation screens as fair: a P/E of 39.3 sits above the sector average of 31.3. Sell-side targets cluster 6.4% above the current quote. Revenue is growing at 3.4% on a 8.3% profit margin.
Risk comes out at 3 of a possible 10, a low reading. With 30-day volatility of 33.7%, a beta of 0.27 and a maximum drawdown of 14.3%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to buy, carrying 5/10 conviction.
Top Market Events
Lead program now in Phase 1 developmentCAMBRIDGE, Mass.Yahoo Finance17dBiogen BIIB Q2 2026 Earnings Call TranscriptThe above button links to Coinbase.Detailed price information for Biogen Inc BIIB-Q from The Globe and Mail including charting and trades.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 188.67
- MACD momentum is positive
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 39.3 versus sector average of 31.3
- Trading above the 200-day average of 188.67
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 39.3 versus sector average of 31.3
- Analyst targets imply +6.4% versus the current price
- Price-to-book of 1.73
Key Metrics & Analysis
Financial Health
Revenue Growth3.40%
Profit Margin8.32%
P/E Ratio39.3
ROE4.58%
ROA5.21%
Debt/Equity44.33
P/B Ratio1.7
Op. Cash Flow$2.9B
Free Cash Flow$1.3B
Industry P/E31.3
Technical Analysis
TrendBullish
RSI62.5
Support$199.58
Resistance$222.85
MA 20$210.27
MA 50$206.06
MA 200$188.67
MACDBullish
VolumeDecreasing
Fear & Greed Index93.66
Valuation
Fair Value$78.30
Target Price$235.57
Upside/Downside6.43%
GradeFair
TypeGrowth
Risk Assessment
Beta0.27
Volatility33.73%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.